• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by CHIEF OPERATING OFFICER Soparkar Peter

    6/20/25 4:29:48 PM ET
    $ADVM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ADVM alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Soparkar Peter

    (Last) (First) (Middle)
    C/O ADVERUM BIOTECHNOLOGIES, INC.
    100 CARDINAL WAY

    (Street)
    REDWOOD CITY CA 94063

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Adverum Biotechnologies, Inc. [ ADVM ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    CHIEF OPERATING OFFICER
    3. Date of Earliest Transaction (Month/Day/Year)
    06/17/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $68.8(1) 06/17/2025 D(2) 40,000(1) (2) 10/29/2029 Common Stock 40,000(1) $0 0 D
    Stock Option (Right to Buy) $10.14 06/17/2025 A(2) 40,000(1) (2) 10/29/2029 Common Stock 40,000(1) $0 40,000(1) D
    Stock Option (Right to Buy) $157.5(1) 06/17/2025 D(3) 4,074(1) (3) 02/19/2030 Common Stock 4,074(1) $0 0 D
    Stock Option (Right to Buy) $10.14 06/17/2025 A(3) 4,074(1) (3) 02/19/2030 Common Stock 4,074(1) $0 4,074(1) D
    Stock Option (Right to Buy) $134.4(1) 06/17/2025 D(4) 13,999(1) (4) 02/15/2031 Common Stock 13,999(1) $0 0 D
    Stock Option (Right to Buy) $10.14 06/17/2025 A(4) 13,999(1) (4) 02/15/2031 Common Stock 13,999(1) $0 13,999(1) D
    Stock Option (Right to Buy) $24.8(1) 06/17/2025 D(5) 15,999(1) (5) 08/05/2031 Common Stock 15,999(1) $0 0 D
    Stock Option (Right to Buy) $10.14 06/17/2025 A(5) 15,999(1) (5) 08/05/2031 Common Stock 15,999(1) $0 15,999(1) D
    Stock Option (Right to Buy) $12.9(1) 06/17/2025 D(6) 25,500(1) (7) 03/07/2032 Common Stock 25,500(1) $0 0 D
    Stock Option (Right to Buy) $10.14 06/17/2025 A(6) 25,500(1) (7) 03/07/2032 Common Stock 25,500(1) $0 25,500(1) D
    Stock Option (Right to Buy) $12.9(1) 06/17/2025 D(6) 13,000(1) (8) 03/07/2032 Common Stock 13,000(1) $0 0 D
    Stock Option (Right to Buy) $10.14 06/17/2025 A(6) 13,000(1) (8) 03/07/2032 Common Stock 13,000(1) $0 13,000(1) D
    Stock Option (Right to Buy) $10.9(1) 06/17/2025 D(9) 23,092(1) (9) 09/13/2032 Common Stock 23,092(1) $0 0 D
    Stock Option (Right to Buy) $10.14 06/17/2025 A(9) 23,092(1) (9) 09/13/2032 Common Stock 23,092(1) $0 23,092(1) D
    Stock Option (Right to Buy) $10.9(1) 06/17/2025 D(10) 16,384(1) (11) 09/13/2032 Common Stock 16,384(1) $0 0 D
    Stock Option (Right to Buy) $10.14 06/17/2025 A(10) 16,384(1) (11) 09/13/2032 Common Stock 16,384(1) $0 16,384(1) D
    Stock Option (Right to Buy) $19.9(1) 06/17/2025 D(12) 45,000(1) (13) 02/11/2034 Common Stock 45,000(1) $0 0 D
    Stock Option (Right to Buy) $10.14 06/17/2025 A(12) 45,000(1) (13) 02/11/2034 Common Stock 45,000(1) $0 45,000(1) D
    Explanation of Responses:
    1. Effective March 21, 2024, the Issuer effected a reverse stock split (the "Reverse Split") whereby every ten shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase ten shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by ten.
    2. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on October 30, 2019 and is fully vested.
    3. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on February 20, 2020 and is fully vested.
    4. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on February 16, 2021 and is fully vested.
    5. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on August 6, 2021 and is fully vested.
    6. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on March 8, 2022.
    7. Twenty-five percent (25%) of the total number of shares subject to the option vested and became exercisable on the first anniversary of February 18, 2022, and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of February 18, 2026, provided the Reporting Person continues to provide Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each such vesting date.
    8. The options vest in equal monthly installments over two years from August 16, 2023, such that all of the shares subject to the option shall become vested and exercisable as of August 16, 2025, provided the Reporting Person continues to provide Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each such vesting date.
    9. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on September 14, 2022 and is fully vested.
    10. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on September 14, 2022.
    11. The options vest in equal monthly installments over three years from September 14, 2022, such that all of the shares subject to the option shall become vested and exercisable as of September 14, 2025, provided the Reporting Person continues to provide Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each such vesting date.
    12. The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on February 12, 2024.
    13. Twenty-five percent (25%) of the total number of shares subject to the option vested and became exercisable on the first anniversary of February 12, 2024, and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of February 12, 2028, provided the Reporting Person continues to provide Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each such vesting date.
    /s/ Aneta Fergson, Attorney-in-Fact 06/20/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ADVM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADVM

    DatePrice TargetRatingAnalyst
    6/25/2024$25.00Outperform
    Oppenheimer
    4/30/2024$30.00Buy
    H.C. Wainwright
    7/7/2022$4.00Hold → Buy
    Truist
    7/23/2021Hold → Neutral
    Cantor Fitzgerald
    7/23/2021$23.00 → $3.00Overweight → Neutral
    Cantor Fitzgerald
    7/23/2021$5.00 → $2.00Market Perform
    SVB Leerink
    More analyst ratings

    $ADVM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CHIEF OPERATING OFFICER Soparkar Peter

      4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

      6/20/25 4:29:48 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CHIEF DEVELOPMENT OFFICER Seyedkazemi Setareh

      4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

      6/20/25 4:29:06 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CHIEF FINANCIAL OFFICER Rubinstein Linda M

      4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

      6/20/25 4:28:29 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADVM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Large owner Leonard Braden Michael bought $188,931 worth of shares (37,000 units at $5.11), increasing direct ownership by 35% to 141,800 units (SEC Form 4)

      4/A - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

      4/28/25 3:31:52 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Leonard Braden Michael bought $188,931 worth of shares (37,000 units at $5.11), increasing direct ownership by 35% to 141,800 units (SEC Form 4)

      4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

      4/28/25 3:24:13 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Leonard Braden Michael bought $1,048,950 worth of shares (350,000 units at $3.00), increasing direct ownership by 35% to 191,800 units (SEC Form 4)

      4 - Adverum Biotechnologies, Inc. (0001501756) (Issuer)

      4/24/25 9:35:07 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADVM
    SEC Filings

    See more
    • SEC Form S-8 filed by Adverum Biotechnologies Inc.

      S-8 - Adverum Biotechnologies, Inc. (0001501756) (Filer)

      6/20/25 4:06:15 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adverum Biotechnologies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Adverum Biotechnologies, Inc. (0001501756) (Filer)

      6/18/25 8:00:26 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Adverum Biotechnologies Inc.

      DEFA14A - Adverum Biotechnologies, Inc. (0001501756) (Filer)

      5/23/25 4:02:43 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADVM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Adverum Biotech with a new price target

      Oppenheimer initiated coverage of Adverum Biotech with a rating of Outperform and set a new price target of $25.00

      6/25/24 8:10:21 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on Adverum Biotech with a new price target

      H.C. Wainwright initiated coverage of Adverum Biotech with a rating of Buy and set a new price target of $30.00

      4/30/24 6:15:49 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adverum Biotech upgraded by Truist with a new price target

      Truist upgraded Adverum Biotech from Hold to Buy and set a new price target of $4.00

      7/7/22 7:11:07 AM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ADVM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      REDWOOD CITY, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 9,740 shares of common stock and restricted stock units (RSUs) for 4,870 shares of common stock to two new employees under Adverum's 2017 Inducement Plan. These awards were approved as an inducement material to the new employees entering into employment with Adverum in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price of $2.22 per share, equal to the per share closing price of Adverum's common st

      6/5/25 4:01:00 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights

      -  Initiated ARTEMIS, the first-ever registrational intravitreal gene therapy trial, in both treatment-experienced and treatment-naive patients with wet AMD -  Presented the first human data mapping cell-level transduction and aflibercept mRNA expression 3.5 years after Ixo-vec administration, establishing the potential for life-long vision preservation REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy to preserve sight for life in highly prevalent ocular diseases, today reported financial results for the first quarter of 2025. The company also provided pipeline highlights and a

      5/14/25 4:05:00 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      REDWOOD CITY, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 32,620 shares of common stock and restricted stock units (RSUs) for 16,310 shares of common stock to seven new employees under Adverum's 2017 Inducement Plan. These awards were approved as an inducement material to the new employees entering into employment with Adverum in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price of $3.33 per share, equal to the per share closing price of Adverum's common

      5/2/25 4:01:00 PM ET
      $ADVM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care